<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84025">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975649</url>
  </required_header>
  <id_info>
    <org_study_id>TTC</org_study_id>
    <secondary_id>245.553C</secondary_id>
    <nct_id>NCT01975649</nct_id>
  </id_info>
  <brief_title>Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder</brief_title>
  <official_title>Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoactive Sexual Desire Disorder ( HSDD ) is very common in postmenopausal women due to a
      reduction in circulating androgen levels. The aim of this study is to evaluate the effects
      of Tribulus Terrestris in premenopausal women with HSDD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoactive Sexual Desire Disorder ( HSDD ) is the most prevalent female sexual dysfunction
      in society mainly in postmenopausal women, and is strongly linked to the quality of life of
      women . The androgen hormones decline over age in the premenopausal period, more sharply
      after menopause. Tribulus terrestris is a plant native to India , recommended in the
      treatment of infertility , low libido and impotence . Its main active ingredient is the
      protodioscin , which has been attributed to an increase in testosterone levels and improved
      sexual function . The aim of this study is to evaluate the effects of Tribulus Terrestris in
      premenopausal women with HSDD .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sexual Desire</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>we will use the &quot;Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum levels of prolactin and thyroid-stimulating hormone (TSH)</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum levels of testosterone and sex hormone-binding globulin (SHBG)</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Menopause</condition>
  <condition>Sexual Abstinence</condition>
  <arm_group>
    <arm_group_label>Tribulus Terrestris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will use Tribulus terrestris (750 mg/day) during 120 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will use placebo for 120 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tribulus Terrestris</intervention_name>
    <description>patients will use 750 mg/day during 120 days</description>
    <arm_group_label>Tribulus Terrestris</arm_group_label>
    <other_name>tribulus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients will use placebo pills with the same shape of the drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one year after last menstrual period

          -  with no use of hormonal replacement therapy within the last 3 months

          -  without any medication, drugs or alcohol.

          -  Healthy patients without systemic or psychiatric disease

        Exclusion Criteria:

          -  Patient smoker (10 cigarettes per day).

          -  Patients with blood pressure &gt; 160/90 mm Hg.

          -  Patient with breast or endometrial carcinoma.

          -  Patients with a history of myocardial infarction.

          -  Patient with Diabetes.

          -  Patient with vaginal bleeding from any source.

          -  Patients with hepatic injury.

          -  Patients with active thrombophlebitis or thromboembolic disorders recent

          -  Patients with interpersonal relationship problems with your relationship or partner

          -  Patients with sexual problems from your partner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selmo Geber, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selmo Geber, MD PhD</last_name>
    <phone>55 31 34099304</phone>
    <email>sjgeber@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karla Zanolla, MD</last_name>
    <phone>55 (31) 9923-2737</phone>
    <email>karlazanolla.souza@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas - Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selmo Geber, MD PhD</last_name>
      <phone>55 31 34099304</phone>
      <email>sjgeber@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Karla Zanolla, MD</last_name>
      <phone>55 (31) 9923-2737</phone>
      <email>karlazanolla.souza@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Selmo Geber, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Selmo Geber</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>postmenopausal</keyword>
  <keyword>hypoactive</keyword>
  <keyword>sexual disorder</keyword>
  <keyword>androgen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
